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Barrett’s esophagus (BE) is established as a premalignant condition in the distal esophagus.
Current surveillance guidelines recommend random biopsies every 1–2 cm at intervals of
3–5 years. Advanced endoscopic imaging of BE underwent several technical revolutions
within the last decade including broad-ﬁeld (red-ﬂag) techniques (e.g., chromoendoscopy)
and small-ﬁeld techniques with confocal laser endomicroscopy (CLE) at the forefront. In
this review we will focus on advanced endoscopic imaging using CLE for the diagnosis and
characterization of BE and associated neoplasia. In addition, we will critically discuss the
technique of CLE and provide some tricks and hints for the daily routine practice of CLE
for diagnosis of BE.
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INTRODUCTION
Barrett’s esophagus (BE) is a metaplastic condition which is char-
acterized by the replacement of normal squamous epithelium
into columnar (intestinal) epithelium within the distal esopha-
gus. There is an ongoing discussion whether the diagnosis of BE
needs histologically proven goblet cells as a prerequisite. At this
time it is also unclear how to proceed clinically with cases without
such goblet cells. The prevalence of BE still remains unknown.
It is estimated that BE affects about 1–3% of the general popu-
lation, although in autopsy studies the prevalence was reported
to be only 0.4–0.9% (Winters et al., 1987; Cameron et al., 1990;
Cameron, 1993; Ormsby et al., 2000; Vieth and Stolte, 2002).
Probably these numbers are even lower according to the above
mentioned discussion.
Gastroesophageal reﬂux disease (GERD) has been identiﬁed as
the major risk factor for the development of BE, while advanced
age (>60 years), obesity,male sex, and white race were additionally
considered to be risk factors of BE (Gaddam and Sharma, 2010).
By itself, BE is considered to be the key risk factor for the
development of esophageal adenocarcinoma (EAC). Compared
to the general population, patients with BE are at a 30- to 50-fold
increased risk for the development of EAC (Tytgat, 1995; Vieth
et al., 2004). In this context it has been suggested that specialized
intestinal metaplasia with goblet cells is the predominant pre-
neoplastic condition which progressively develops to low-grade
intraepithelial neoplasia (LGIEN), to high-grade intraepithelial
Abbreviations: EAC, esophageal adenocarcinoma; FICE, Fujinon intelligent color
enhancement; HD-WLE, high-deﬁnition white light endoscopy; HGIEN, high-
grade intraepithelial neoplasia; iCLE, integrated confocal laser endomicroscopy;
LGIEN, low-grade intraepithelial neoplasia; NBI, narrow band imaging; pCLE,
probe-based confocal laser endomicroscopy.
neoplasia (HGIEN), and than to EAC (Reid et al., 1993; Vieth,
2007).Nevertheless, recent data indicate that evenpatientswithout
goblet cells in the columnar lining at the distal esophagus show the
same chromosomal and DNA content abnormalities and genetic
instabilities compared to goblet cell containing esophageal meta-
plasia (Liu et al., 2009;Vieth and Barr, 2009). Moreover, one recent
multicenter study including 210 patients with BE and LGIEN with
a mean follow-up of 6.2 years demonstrated that patients with BE
and LGIEN have a low annual incidence of about 0.44%/year of
EAC which is similar to patients with non-dysplastic BE. In addi-
tion, no “convincing” risk factors for the progression of LGIEN to
EAC could be found other than LGIEN itself preferably conﬁrmed
by a second opinion (Wani et al., 2011).
Therefore, all metaplasia in the columnar lined esophagus may
already be on the path to cancer and need distinct examination
by the exploiting team of an endoscopist and histopathologist.
Hence, current guidelines from most gastroenterological soci-
eties worldwide recommend endoscopic screening for the detec-
tion of BE for patients with chronic GERD. If a BE-segment is
identiﬁed four-quadrant random biopsies at 2-cm intervals are
recommended in patients without suspicion of HGIEN or at
1-cm intervals in patients with suspected HGIEN of metaplas-
tic tissue supplemented with targeted biopsies of grossly sus-
picious areas according to the Seattle protocol (Peters et al.,
2008).
While the presence of intraepithelial neoplasia or early adeno-
carcinoma within a BE-segment may occur patchy, standard white
light endoscopy with random biopsy may miss a certain quantum
of lesions. Moreover, the random biopsy protocol has several limi-
tations, as it is time-consuming, expensive, and prone to sampling
error because less than 10% of the surface area is sampled (Hwang,
2009).
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Taken into account the tremendous increasing incidence of BE
(about 350% over the past 20 years), the need for improved imag-
ing techniques for diagnosis and characterization of BE becomes
obvious.
Indeed, endoscopic imaging of BE has seen several techni-
cal revolutions within the last two decades. These new imaging
techniques can be subdivided into broad-ﬁeld techniques (“red-
ﬂag”) which allow the examination of the whole luminal surface
area and small-ﬁeld imaging techniques which provide an optical
biopsy of the tissue. Red-ﬂag techniques include both, dye-based
(e.g., methylene blue) and dye-less chromoendoscopy (narrow
band imaging, NBI; FICE; i-scan) (Figure 1) and magniﬁcation
endoscopy while small-ﬁeld imaging techniques include endocy-
toscopy and confocal laser endomicroscopy (CLE; Neumann et al.,
2012).
Here,we will focus on advanced endoscopic imaging using CLE
for the diagnosis and characterization of BE and associated neo-
plasia. In addition, we will critically discuss the technique of CLE
and provide some tricks and hints for the daily routine practice of
CLE for diagnosis of BE.
TECHNICAL BACKGROUND
Confocal laser endomicroscopy is based on the principle of tis-
sue illumination with a blue laser light (488 nm wave length) after
application of ﬂuorescence agents which can either be applied top-
ically (e.g., acriﬂavine hydrochloride, cresyl violet) or systemically
(ﬂuorescein sodium; Neumann et al., 2010).
Up to now, only the topical applied ﬂuorescence agents
enabled imaging of cell nuclei which is essential to differ-
entiate between LGIEN and HGIEN according to the Vienna
classiﬁcation of gastrointestinal neoplasia (Schlemper et al.,
2000). While acriﬂavine accumulates in nuclei a potential muta-
genic risk of this drug is discussed. Cresyl violet was recently
introduced as an alternative ﬂuorescence agent for confocal
imaging which provides cytoplasmic enrichment and thereby
FIGURE 1 |Typical endoscopic appearance of Barrett’s esophagus
imaged using narrow band imaging (NBI) with single mucosal tears
proximal to the esophagogastric junction.
negative visualization of nuclear morphology (Goetz et al.,
2009).
Nevertheless, the most widely used ﬂuorescent agent to date
is intravenous ﬂuorescein (mostly 3–5 ml of a 10% solution).
Fluorescein is a non-toxic agent and FDA-cleared for diagnos-
tic angiography of the retina for years. Importantly, as ﬂuores-
cein is a non-selective vascular contrast agent, only architectural
details could be imaged. The safety of intravenous ﬂuorescein for
confocal imaging was recently demonstrated in a large multicen-
ter study, including 16 centers and nearly 2300 gastrointestinal
endomicroscopy procedures (Wallace et al., 2010a). In this study
no serious adverse events were reported. Mild adverse events
occurred in 1.4% of individuals, including transient hypotension
without shock (0.5%), nausea (0.39%), injection site erythema
(0.35%), self-limiteddiffuse rash (0.04%),andmild epigastric pain
(0.09%).
Currently, two different endomicroscopy systems are commer-
cially available (Neumann et al., 2010). One is integrated into the
distal tip of a standard, high-resolution endoscope (iCLE; Pentax,
Tokyo, Japan) (Figure 2) and one is probe-based (pCLE; Cellvizio,
Mauna Kea Technologies, Paris, France) (Figure 3) capable of pas-
sage through the accessory channel of nearly any endoscope. Both
systems use an incident 488 nm wavelength laser and allow both,
real-time observation and post hoc analysis of the tissue at about
1000-fold magniﬁcation.
The iCLE-system has an imaging plane depth ranging from 0
to 250 μm. The optical slice thickness is 7 μm, with lateral and
axial resolutions of 0.7 μm. The observer can manually adjust
the laser power output at the tissue surface ranging from 0 to
1000 μW. Confocal images are captured at a manually adjustable
frame rate of 1.6 images/s at a resolution of 1024× 512 pixels, or at
0.8 images/s at a resolution of 1024× 1024 pixels with a confocal
image ﬁeld of view of 475× 475 μm.
The pCLE-system offers different endomicroscopy-probes
for luminal and non-luminal confocal exploration. Probes for
endomicroscopy during esophagogastroduodenoscopy require
accessory channels of 2.8 mm and have a working length of 3 m.
Lateral resolution is 1μm which constitutes to a 43% decrease in
resolution compared to the iCLE-system (Bisschops and Bergman,
2010). Confocal images are streamed at a video frame rate of
12 frames/s. The system has a ﬁxed laser power and a ﬁxed image
plane depth of 55–65 μm.
In order to achieve complete agreement between confocal diag-
nosis and biopsy acquisition for subsequent histopathological
diagnosis one has to keep in mind that the working channel of
the iCLE-system is located 5 mm to the right of the confocal lens.
Therefore, when suction is applied to the mucosa, the resulting
intramucosal hemorrhage is located 5 mm to the right from the
area which has been evaluated using iCLE. For pCLE mild pres-
sure is performed with the confocal probe to the tissue and the
resulting reddishmucosa can guide subsequent biopsy acquisition.
Moreover, we recommend attaching a clear cap at the distal tip of
the endoscope for pCLE-imaging as motion artifacts substantially
impede confocal imaging at the squamocolumnar junction. Even
administration of antispasmodic agents (e.g., Buscopan) may help
to stabilize the confocal probe for subsequent high-magniﬁcation
imaging of the mucosa.
Frontiers in Oncology | Gastrointestinal Cancers May 2012 | Volume 2 | Article 42 | 2
Neumann et al. CLE in Barrett
ENDOMICROSCOPY OF BARRETT’S ESOPHAGUS
The ﬁrst study of confocal imaging for diagnosis of BE was intro-
duced in 2006 and included 63 patients (Kiesslich et al., 2006). In
this pioneer study by Kiesslich and coworkers iCLE was proven to
reliable identify different epithelial cell types at the squamocolum-
nar junction, including squamous epithelium, gastric epithelium,
and specialized intestinal epithelium containing goblet cells. Gob-
let cells could easily be identiﬁed as CLE displayed the mucin of
goblet cells as very dark oval to round appearing structures within
the columnar lined epithelium. In patients with BE-associated
neoplasia CLE imaged large, irregular sheets of black cells which
showed a marked dark abrupt contrast to the surrounding tissue
and loss of regular architecture with irregular lumina of differ-
ent diameter. The dark contrast is probably due to the lower
pH within neoplastic cells. Additionally, the brightness of the
FIGURE 2 | (A) Confocal laser endomicroscopy using the integrated device
(iCLE). Regular shaped columnar lined epithelium with goblet cells (arrows)
is clearly visible. (B) Histological image of Barrett’s epithelium with
numerous typical goblet cells that replaced the regular squamous
epithelium in the distal esophagus (H&E 200×).
lamina propria became heterogeneous according to an increased
and irregular vasculature with ﬂuorescein leakage. Based on these
parameters the authors proposed a Confocal BE-classiﬁcation to
predict histopathology in the distal esophagus. In vivo imaging
could predict BE and associated neoplasia with a sensitivity of 98
and 93%, speciﬁcity of 94 and 98%, and accuracy of 97%, respec-
tively. Of note, most of the patients with neoplasia (80%) had
mucosal irregularities or focal lesions that could be detected by
high-resolution white light endoscopy.
This is of particular importance when taken into account the
data of Bajbouj et al. (2010) where pCLE was compared with
a standard four-quadrant biopsy protocol for the evaluation of
neoplasia in BE. In this multicenter study a total of 670 pCLE-
matched biopsies were obtained from 68 patients. The authors
studied the diagnostic accuracy of pCLE for real-time diagnosis
during ongoing endoscopy and in a blinded fashion by scoring the
confocal images without having the endoscopic image available.
FIGURE 3 | (A) pCLE image of high-grade intraepithelial neoplasia in patient
with BE. Confocal imaging demonstrated dark, irregularly thickened
epithelial cells, and dilated irregular vessels. (B) Histological image of
Barrett’s esophagus with high-grade intraepithelial neoplasia. Cytological
and architectural atypia is visible. The nuclei are larger in size with increased
chromaticity, and loss of cell polarity. Architectural distortion is characterized
by a back-to-back crypt pattern and focal cribriform areas.
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The study demonstrates that correct image interpretation depends
on simultaneous elucidation of endoscopic and confocal images,
as on a per-patient basis, a signiﬁcant decrease in speciﬁcity from
95 to 59% was observed when investigators were blinded to the
endoscopic ﬁndings.
Therefore, simultaneous interpretation of macroscopic and
microscopic images is essential as “The eye sees only what the mind
is prepared to comprehend” (Henri Bergson 1859–1941, French
philosopher).
In another prospective two-center trial 38 consecutive patients
with BE were examined with standard high-resolution white light
endoscopy and pCLE (Pohl et al., 2008). In a per-biopsy analysis,
sensitivity and speciﬁcity for two independent investigators were
75 and 89%, and 75 and 91%, respectively, translating at best into
a positive predictive value of 44% and a negative predictive value
of 99% (Pohl et al., 2008).
One prospective, randomized, double-blind, controlled,
crossover trial at a tertiary referral center evaluated whether iCLE
with targeted mucosal biopsy improves the diagnostic yield of
endoscopically inapparent, BE-associated neoplasia compared to
standard endoscopy with a four-quadrant, random biopsy pro-
tocol (Dunbar et al., 2009). Overall, 39 patients completed the
study protocol. It was found that iCLE with targeted biopsy almost
doubled the diagnostic yield for neoplasia (34 vs. 17%) and was
equivalent to the standard protocol for the ﬁnal diagnosis of neo-
plasia. Moreover, two thirds of patients in the surveillance group
did not need any mucosal biopsies at all. Another important lesson
from the study is that there were two patients with HGIEN only
identiﬁed using iCLE, whereas another two patients with HGIEN
were only identiﬁed by standard white light endoscopy with ran-
dom biopsies. This illustrates the limitation of CLE, which is a
small-ﬁeld imaging technique, therefore prone to sampling error.
Wallace et al. (2010b) determined the preliminary accuracy
and interobserver agreement of pCLE in BE using a prospective,
double-blind review of confocal images of BE after a training set
of 20 images with known histology was reviewed to standardize
image interpretation. The sensitivity for the diagnosis of neopla-
sia for the 11 attending endoscopists from different international
centers was 88%, and the speciﬁcity was 96% with a substantial
agreement on the pCLE diagnosis (86%, κ 0.72; 95% conﬁdence
interval, 0.58–0.86). These results suggest that pCLE for the diag-
nosis of neoplasia in BE has a very high accuracy and reliability
and can relatively easy be learned and used (Figure 4).
Very recently the results of a large prospective international
multicenter study on BE including ﬁve tertiary referral centers
were presented (Sharma et al., 2011). In this study, 101 consec-
utive patients with BE were examined by high-deﬁnition white
light endoscopy (HD-WLE),NBI, and pCLE,and the ﬁndingswere
recorded before biopsy samples were obtained. The sensitivity and
speciﬁcity for HD-WLE were 34 and 93%, respectively, compared
with 68 and 88%, respectively, for HD-WLE or pCLE which was
statistically signiﬁcant different. The sensitivity and speciﬁcity for
HD-WLE or NBI were 45 and 88%, respectively, compared with
76 and 84%, respectively, for HD-WLE,NBI, or pCLE which again
was statistically signiﬁcant. Therefore, pCLE combined with HD-
WLE signiﬁcantly improved the ability to detect neoplasia in BE
patients compared to HD-WLE alone.
FIGURE 4 | (A) In vivo endomicroscopy of advanced esophageal
adenocarcinoma in patient with long-segment Barrett’s esophagus using
the probe-based device (pCLE). Note the clear cap at the distal tip of the
endoscope to avoid motion artifacts. (B) Corresponding endomicroscopic
appearance of adenocarcinoma in a patient with Barrett’s esophagus.
Irregular, dark cells with high contrast to the surrounding tissue indicate
advanced neoplasia. (C) Histological image of moderately differentiated
adenocarcinoma in a patient with Barrett’s esophagus with loss of regular
architecture and superﬁcial erosion.
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In order to discriminate new diagnostic criteria for dysplastic
BE-tissue again the group from Kansas City evaluated multi-
ple pCLE criteria including the epithelial surface, epithelial cell,
and gland morphology (Gaddam et al., 2011). By using these
criteria the overall accuracy in diagnosing dysplasia was 82%.
Interestingly, no differences in image interpretation were observed
between experts and non-experts in confocal imaging. More
importantly, after a structured teaching session, accuracy, and
agreement between experienced and non-experienced observers
was not different, suggesting a short learning curve of image
interpretation.
Recently, a consensus of pCLE users for standardization of
image criteria was introduced. The so called “Miami classiﬁca-
tion” described substantial parameters to differentiate between
normal squamous epithelium, non-dysplastic Barrett’s epithe-
lium, HGIEN, and adenocarcinoma in BE (Wallace et al., 2011).
Following this classiﬁcation, normal squamous epithelium is char-
acterized by ﬂat cells without crypts or villi and bright vessels
within papillae, representing the intra papillary capillary loops.
Non-dysplastic BE showed uniform villiform architecture with
columnar cells and dark appearing goblet cells. In contrast, pCLE
images demonstrating villiform structures and dark, irregularly
thickened epithelial borders and dilated irregular vessels were spe-
ciﬁc for BEwithHGIEN.Adenocarcinoma inBEwas characterized
by disorganized or a completely loss of villiform structures and
crypts, dark columnar cells, and dilated irregular vessels.
SUMMARY
Barrett’s esophagus is a premalignant condition as a sequel of long
standing GERD. Therefore, surveillance is of paramount impor-
tance. Nevertheless, the patchy and inhomogeneous distribution
of intraepithelial neoplasia within a Barrett’s segment makes a cor-
rect diagnosis often difﬁcult. Columnar lined epithelium is often
a mosaic of different cell types consisting of junctional and car-
diac epithelium, specialized intestinal metaplasia with or without
intraepithelial neoplasia. Random biopsies are prone to sampling
error and may miss a quantum of lesions. Besides, they are cost
expensive and may even result in severe complications (Vieth and
Stolte, 2000; Mannath et al., 2010). Enhanced endoscopic imaging
techniques seem to have overcome these limitations and are there-
fore highly recommended to improve diagnostic outcome of BE
patients. CLE allows real-time in vivo assessment of architectural
details at a comparable quality to standard histopathology. This is
the base for saving time and thus money due to possible immedi-
ate further interventional steps such as local endoscopic resection
in case of any suspicious lesions. Various large and multicenter
studies have shown a substantial accuracy of CLE for diagno-
sis of BE and associated neoplasia. Therefore, this new imaging
technique offers the potential of enhanced endoscopic imaging of
BE for better surveillance and even to guide further endoscopic
management (Leung et al., 2009). Moreover, CLE has great future
potential in the assessment of BE as far as further improvement
of the technique, which allows visualization of submucosal struc-
tures and new dye agents which allow speciﬁc visualization of
cellular features, become available. This will allow a more pre-
cise risk stratiﬁcation and triage of the patients: surgery vs. local
endoscopic resection. Even more, molecular imaging with spe-
ciﬁc ﬂuorescence-labeled probes against Barrett’s epithelium may
enhance current concepts of Barrett’s management. Neverthe-
less, despite these exiting ongoing developments and even from
a medical-legal point of view more data are needed to justify
this approach in the clinical setting. In many countries a diag-
nosis made on base of tissue (virtual or histologically) is limited
to board-certiﬁed pathologists also for legal reasons. Regulations
may need revision according to these newly available techniques.
Up to now, four-quadrant random biopsies according to the Seat-
tle protocol still remained the gold standard for diagnosis and
characterization of BE. More relevant and thus localized so called
smarter biopsies due to the new imaging techniques may simplify
and improve surveillance and planning of interventions.
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